GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Cyclically Adjusted FCF per Share

ARCA biopharma (FRA:HQ10) Cyclically Adjusted FCF per Share : €-192.75 (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ARCA biopharma's adjusted free cash flow per share for the three months ended in Jun. 2024 was €-2.024. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-192.75 for the trailing ten years ended in Jun. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 43.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 47.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ARCA biopharma was 52.40% per year. The lowest was -4.00% per year. And the median was 16.40% per year.

As of today (2025-05-22), ARCA biopharma's current stock price is €25.92. ARCA biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €-192.75. ARCA biopharma's Cyclically Adjusted Price-to-FCF of today is .


ARCA biopharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ARCA biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Cyclically Adjusted FCF per Share Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,232.80 -1,231.09 -703.48 -386.75 -253.21

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -295.28 -278.17 -253.21 -215.63 -192.75

Competitive Comparison of ARCA biopharma's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, ARCA biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

ARCA biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ARCA biopharma's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-2.024/132.5538*132.5538
=-2.024

Current CPI (Jun. 2024) = 132.5538.

ARCA biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -115.143 100.428 -151.976
201412 -108.857 99.070 -145.649
201503 -205.571 99.621 -273.529
201506 -119.000 100.684 -156.668
201509 -51.000 100.392 -67.339
201512 -57.310 99.792 -76.125
201603 -83.048 100.470 -109.568
201606 -74.738 101.688 -97.423
201609 -79.381 101.861 -103.300
201612 -86.810 101.863 -112.966
201703 -96.714 102.862 -124.631
201706 -102.628 103.349 -131.629
201709 -62.906 104.136 -80.073
201712 -64.473 104.011 -82.166
201803 -39.556 105.290 -49.799
201806 -30.141 106.317 -37.579
201809 -21.156 106.507 -26.330
201812 -18.438 105.998 -23.057
201903 -18.480 107.251 -22.840
201906 -10.029 108.070 -12.301
201909 -6.339 108.329 -7.757
201912 -7.835 108.420 -9.579
202003 -11.496 108.902 -13.993
202006 -6.228 108.767 -7.590
202009 -3.373 109.815 -4.071
202012 -3.107 109.897 -3.748
202103 -4.266 111.754 -5.060
202106 -2.582 114.631 -2.986
202109 -3.457 115.734 -3.959
202112 -3.650 117.630 -4.113
202203 -3.251 121.301 -3.553
202206 -2.065 125.017 -2.189
202209 -2.101 125.227 -2.224
202212 -1.174 125.222 -1.243
202303 -1.241 127.348 -1.292
202306 -0.534 128.729 -0.550
202309 -1.302 129.860 -1.329
202312 -0.805 129.419 -0.824
202403 -1.164 131.776 -1.171
202406 -2.024 132.554 -2.024

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ARCA biopharma  (FRA:HQ10) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ARCA biopharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines